CervoMed Inc.
CRVO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $19 | $8 | $1 | $8 |
| G&A Expenses | $9 | $7 | $2 | $7 |
| SG&A Expenses | $9 | $7 | $2 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$10 | -$7 | $0 | $9 |
| Operating Expenses | $18 | $8 | $3 | $25 |
| Operating Income | -$18 | -$8 | -$3 | -$25 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $6 | -$2 | $0 |
| Pre-Tax Income | -$16 | -$2 | -$6 | -$25 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$16 | -$2 | -$6 | -$24 |
| % Margin | – | – | – | – |
| EPS | -2.02 | -0.82 | -11.2 | -18.51 |
| % Growth | -146.3% | 92.7% | 39.5% | – |
| EPS Diluted | -2.02 | -0.82 | -11.2 | -18.51 |
| Weighted Avg Shares Out | 8 | 3 | 1 | 1 |
| Weighted Avg Shares Out Dil | 8 | 3 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$18 | -$8 | -$6 | -$16 |
| % Margin | – | – | – | – |